NASDAQ:ERAS Erasca (ERAS) Stock Price, News & Analysis → Pentagon contract could send this $2 AI stock soaring (From Behind the Markets) (Ad) Free ERAS Stock Alerts $1.88 -0.05 (-2.59%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$1.86▼$1.9550-Day Range$1.73▼$2.5552-Week Range$1.51▼$3.38Volume533,372 shsAverage Volume781,148 shsMarket Capitalization$284.80 millionP/E RatioN/ADividend YieldN/APrice Target$7.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Erasca alerts: Email Address Erasca MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside317.8% Upside$7.83 Price TargetShort InterestBearish9.88% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.92) to ($0.99) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.27 out of 5 starsMedical Sector634th out of 909 stocksPharmaceutical Preparations Industry286th out of 423 stocks 3.4 Analyst's Opinion Consensus RatingErasca has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageErasca has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.88% of the float of Erasca has been sold short.Short Interest Ratio / Days to CoverErasca has a short interest ratio ("days to cover") of 11, which indicates bearish sentiment.Change versus previous monthShort interest in Erasca has recently decreased by 1.66%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldErasca does not currently pay a dividend.Dividend GrowthErasca does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ERAS. Previous Next 2.8 News and Social Media Coverage News SentimentErasca has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Medical companies.Search Interest4 people have searched for ERAS on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Erasca to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Erasca insiders have not sold or bought any company stock.Percentage Held by Insiders29.80% of the stock of Erasca is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions67.78% of the stock of Erasca is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Erasca are expected to decrease in the coming year, from ($0.92) to ($0.99) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Erasca is -2.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Erasca is -2.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioErasca has a P/B Ratio of 0.89. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsPentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...Get all the info here >>> About Erasca Stock (NASDAQ:ERAS)Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.Read More ERAS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ERAS Stock News HeadlinesApril 24, 2024 | globenewswire.comErasca Announces Three Presentations at the 2024 ASCO Annual MeetingApril 16, 2024 | finance.yahoo.comInstitutional investors may adopt severe steps after Erasca, Inc.'s (NASDAQ:ERAS) latest 11% drop adds to a year lossesApril 24, 2024 | Behind the Markets (Ad)Pentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...April 9, 2024 | fool.comErasca (NASDAQ: ERAS)April 3, 2024 | markets.businessinsider.comErasca’s Promising Naporafenib Data and Financial Stability Merit a Buy RatingApril 1, 2024 | finance.yahoo.comErasca, Inc. (NASDAQ:ERAS) Q4 2023 Earnings Call TranscriptMarch 31, 2024 | seekingalpha.comErasca, Inc. (ERAS) R&D Update Call and Q4 2023 Earnings Call TranscriptMarch 29, 2024 | finanznachrichten.deErasca, Inc.: Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial ResultsApril 24, 2024 | Behind the Markets (Ad)Pentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...March 29, 2024 | finance.yahoo.comErasca Inc (ERAS) Aligns with EPS Projections, Reveals Robust Balance Sheet and Key Clinical ...March 29, 2024 | markets.businessinsider.comErasca’s Strong Clinical Data and Enhanced Financial Position Support Buy RatingMarch 28, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Celcuity (CELC) and Erasca (ERAS)March 28, 2024 | msn.comErasca to get $45M funding via private placementMarch 28, 2024 | marketwatch.comErasca Shares Climb After 4Q Loss Narrows, $45 Million Private PlacementMarch 27, 2024 | investorplace.comERAS Stock Earnings: Erasca Beats EPS for Q4 2023March 27, 2024 | globenewswire.comErasca Announces $45 Million Oversubscribed Private Placement FinancingMarch 27, 2024 | globenewswire.comErasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial ResultsMarch 21, 2024 | msn.comOcugen hits a 52-week high after decision to lower quorum requirementFebruary 27, 2024 | finance.yahoo.comERAS Mar 2024 2.000 putFebruary 17, 2024 | finance.yahoo.comERAS Mar 2024 2.500 callFebruary 15, 2024 | msn.comErasca collaborates with Novartis on cancer therapy trialsFebruary 14, 2024 | finance.yahoo.comErasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 TrialsFebruary 1, 2024 | finance.yahoo.comErasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceJanuary 9, 2024 | finance.yahoo.comIs Erasca (NASDAQ:ERAS) In A Good Position To Invest In Growth?January 7, 2024 | benzinga.comErasca Stock (NASDAQ:ERAS), Analyst Ratings, Price Targets, PredictionsJanuary 6, 2024 | msn.comB of A Securities Downgrades Erasca (ERAS)January 3, 2024 | finance.yahoo.comErasca to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceSee More Headlines Receive ERAS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Erasca and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/27/2024Today4/24/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ERAS CUSIPN/A CIK1761918 Webwww.erasca.com Phone858-465-6511FaxN/AEmployees129Year FoundedN/APrice Target and Rating Average Stock Price Target$7.83 High Stock Price Target$11.00 Low Stock Price Target$6.00 Potential Upside/Downside+299.7%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-125,040,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-35.60% Return on Assets-29.03% Debt Debt-to-Equity RatioN/A Current Ratio12.26 Quick Ratio12.26 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.10 per share Price / Book0.93Miscellaneous Outstanding Shares151,490,000Free Float106,349,000Market Cap$296.92 million OptionableOptionable Beta1.10 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Jonathan E. Lim M.D. (Age 52)Co-Founder, Chairman & CEO Comp: $940.32kDr. David M. Chacko M.D. (Age 40)CFO & Chief Business Officer Comp: $616.76kDr. Michael D. Varney Ph.D. (Age 66)Chairman of Research & Development, Scientific Advisory Board Member and Director Comp: $83.26kDr. Nik Chetwyn Ph.D.Chief Operating OfficerMr. Ebun S. Garner J.D. (Age 52)Esq., General Counsel & Corporate Secretary Comp: $510.98kDr. Lisa Tesvich-Bonora Ph.D.Chief People OfficerMr. Brian L. Baker CPA (Age 57)M.S., Senior Vice President of Finance Ms. Chandra D. Lovejoy M.S. (Age 53)Chief Regulatory Affairs Officer Dr. Robert Shoemaker Ph.D. (Age 43)Senior Vice President of Research Dr. Shannon R. Morris M.D. (Age 54)Ph.D., Chief Medical Officer More ExecutivesKey CompetitorsNeoleukin TherapeuticsNASDAQ:NLTXKamadaNASDAQ:KMDAVerrica PharmaceuticalsNASDAQ:VRCAContineum TherapeuticsNASDAQ:CTNMRenovaroNASDAQ:RENBView All CompetitorsInsiders & InstitutionsSanders Morris Harris LLCSold 563,189 shares on 4/11/2024Ownership: 0.008%Sierra Summit Advisors LLCBought 105,711 shares on 2/22/2024Ownership: 0.070%PFM Health Sciences LPSold 1,355,122 shares on 2/15/2024Ownership: 1.705%Pale Fire Capital SEBought 144,000 shares on 2/14/2024Ownership: 0.123%Pennant Investors LPBought 166,200 shares on 2/14/2024Ownership: 0.110%View All Insider TransactionsView All Institutional Transactions ERAS Stock Analysis - Frequently Asked Questions Should I buy or sell Erasca stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Erasca in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ERAS shares. View ERAS analyst ratings or view top-rated stocks. What is Erasca's stock price target for 2024? 5 equities research analysts have issued 12-month price targets for Erasca's shares. Their ERAS share price targets range from $6.00 to $11.00. On average, they predict the company's share price to reach $7.83 in the next year. This suggests a possible upside of 317.8% from the stock's current price. View analysts price targets for ERAS or view top-rated stocks among Wall Street analysts. How have ERAS shares performed in 2024? Erasca's stock was trading at $2.13 at the beginning of the year. Since then, ERAS shares have decreased by 12.0% and is now trading at $1.8750. View the best growth stocks for 2024 here. When is Erasca's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our ERAS earnings forecast. How were Erasca's earnings last quarter? Erasca, Inc. (NASDAQ:ERAS) announced its quarterly earnings data on Wednesday, March, 27th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.04. What ETFs hold Erasca's stock? ETFs with the largest weight of Erasca (NASDAQ:ERAS) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Loncar China Biopharma ETF (CHNA). When did Erasca IPO? Erasca (ERAS) raised $262 million in an initial public offering (IPO) on Thursday, July 15th 2021. The company issued 17,500,000 shares at $14.00-$16.00 per share. Who are Erasca's major shareholders? Erasca's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Sanders Morris Harris LLC (0.01%). Insiders that own company stock include Alexander W Casdin, Bihua Chen, Jonathan E Lim and Valerie Denise Harding Start. View institutional ownership trends. How do I buy shares of Erasca? Shares of ERAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ERAS) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe #1 Crypto for 2024InvestorPlaceFed launches fourth dollar overhaulStansberry ResearchNew Trump BombshellThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Erasca, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
